United Therapeutics director granted equity awards

United Therapeutics director Jan Malcolm received equity compensation grants.

Rhea-AI Filing Summary

United Therapeutics director Jan Malcolm received equity compensation grants. On July 22, 2026, Malcolm was granted 380 restricted stock units and stock options for 1,190 shares of common stock at an exercise price of $527.07, as annual non-employee director awards. These awards vest on the earlier of the one-year anniversary of the grant date or the next Annual Meeting of Shareholders, anticipated on June 25, 2027. Following the grants, Malcolm directly holds 380 RSUs, 3,570 stock options and 450 common shares. The awards were reported as made pursuant to a Rule 10b5-1 trading arrangement.

Insider Trade Summary 10b5-1

Grant/Award: 1,570 shares

Grant/Award 3 txns

Insider MALCOLM JAN

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Restricted Stock Unit F1, F2, F3, F4	380	$0.00	$0.00
Grant/Award	Stock Option F2, F3	1,190	$0.00	$0.00
holding	Common Stock	--	--	--

Holdings After Transaction: Restricted Stock Unit — 380 contracts (Direct); Stock Option — 3,570 contracts (Direct); Common Stock — 450 shares (Direct)

Footnotes (4)

1. F1. Each restricted stock unit represents the right to receive, following vesting, one share of United Therapeutics Corporation common stock.
2. F2. Annual non-employee director award.
3. F3. Annual non-employee director awards become fully vested on the earlier to occur of (a) the one-year anniversary of the grant date; or (b) the date of the next Annual Meeting of Shareholders following the grant date. June 25, 2027 is the anticipated date of the next Annual Meeting of Shareholders.
4. F4. Not applicable as restricted stock units do not have an expiration date.

Key Figures

RSUs Granted: 380 units Options Granted: 1,190 shares Option Exercise Price: $527.07 per share +4 more

7 metrics

RSUs Granted 380 units Restricted stock units granted to director on July 22, 2026

Options Granted 1,190 shares Stock options on common stock granted on July 22, 2026

Option Exercise Price $527.07 per share Conversion or exercise price for stock options

Option Expiration July 22, 2033 Expiration date of the granted stock options

RSU Holdings After Grant 380 units Total restricted stock units held directly after transaction

Option Holdings After Grant 3,570 shares Total stock options held directly after transaction

Common Stock Holdings 450 shares Directly held United Therapeutics common shares after reported transactions

Key Terms

Restricted Stock Unit, Annual non-employee director award, Annual Meeting of Shareholders

3 terms

Restricted Stock Unit financial

"Each restricted stock unit represents the right to receive, following vesting, one share"

A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.

Annual non-employee director award financial

"Annual non-employee director award."

Annual Meeting of Shareholders financial

"the date of the next Annual Meeting of Shareholders following the grant date"

A yearly gathering where a company’s owners (shareholders) vote on key items like electing the board, approving executive pay, and ratifying auditors, and receive updates on performance and strategy. Think of it as an annual town hall for owners: it matters to investors because outcomes and disclosures can affect leadership, corporate direction, dividend and governance policies, and therefore the company’s risk and potential return.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What equity awards did United Therapeutics (UTHR) director Jan Malcolm receive?

Jan Malcolm received 380 restricted stock units and stock options for 1,190 shares of United Therapeutics common stock. Both awards were described as annual non-employee director grants made on July 22, 2026, as part of the company’s director compensation program.

What is the exercise price and term of Jan Malcolm’s United Therapeutics (UTHR) stock options?

Malcolm’s stock options are exercisable at $527.07 per share for 1,190 common shares. These options were granted on July 22, 2026 and are scheduled to expire on July 22, 2033, subject to the vesting conditions tied to the company’s director awards.

When do Jan Malcolm’s United Therapeutics (UTHR) director awards vest?

The awards become fully vested on the earlier of the one-year anniversary of July 22, 2026 or the date of the next Annual Meeting of Shareholders. That next meeting is anticipated for June 25, 2027, according to the award footnotes.

How many United Therapeutics (UTHR) shares does Jan Malcolm hold after these awards?

After the July 22, 2026 awards, Malcolm directly holds 380 RSUs, 3,570 stock options, and 450 shares of United Therapeutics common stock. These positions reflect the updated post-transaction holdings reported for this director.

Were Jan Malcolm’s United Therapeutics (UTHR) awards made under a Rule 10b5-1 plan?

The transactions were affirmed as made under a Rule 10b5-1 trading arrangement, based on the checked Rule 10b5-1 box. This indicates the equity grants were executed pursuant to a pre-established trading or award plan framework.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 07/23/2026 - 04:43 PM Accepted by SEC EDGAR 07/23/2026 - 04:43 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

MALCOLM JAN

(Last) (First) (Middle)

C/O UNITED THERAPEUTICS CORPORATION

1000 SPRING STREET

(Street)

SILVER SPRING MARYLAND 20910

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
UNITED THERAPEUTICS Corp [ UTHR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/22/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock								450	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Unit	$0.00(1)	07/22/2026		A		380(2)		06/25/2027(3)	(4)	Common Stock	380	$0.00	380	D
Stock Option	$527.07	07/22/2026		A		1,190(2)		06/25/2027(3)	07/22/2033	Common Stock	1,190	$0.00	3,570	D

Explanation of Responses:

1. Each restricted stock unit represents the right to receive, following vesting, one share of United Therapeutics Corporation common stock.

2. Annual non-employee director award.

3. Annual non-employee director awards become fully vested on the earlier to occur of (a) the one-year anniversary of the grant date; or (b) the date of the next Annual Meeting of Shareholders following the grant date. June 25, 2027 is the anticipated date of the next Annual Meeting of Shareholders.

4. Not applicable as restricted stock units do not have an expiration date.

Remarks:

	/s/ John S. Hess, Jr. under Power of Attorney	07/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)